Researchers in Japan have developed a test to predict sudden cardiac death in hemodialysis patients. The test uses a combination of nuclear medicine, C-reactive protein, and electrocardiogram. Akiyoshi Hashimoto, MD, and colleagues reported results of the research at the International Conference on Nuclear Cardiology in Madrid, Spain, in May, according to an article in Medical News Today.
“Hemodialysis patients are at increased risk of sudden cardiac death because they often have latent ischemic heart disease which reduces blood flow to the heart,” Dr. Hashimoto said.
“For the first time there is a way to predict sudden cardiac death in hemodialysis patients. In a clinical setting [beta-methyl-p-iodophenyl-pentadecanoic acid] BMIPP scintigraphy can be used in hemodialysis patients who are identified as high risk by abnormal Q wave and increased C-reactive protein. Abnormal BMIPP identifies specific myocardial injury which could be an effective therapeutic target for preventing sudden cardiac death,” he added.